Differentiated Thyroid Carcinoma
1 medicine
Differentiated thyroid carcinoma is the most common form of thyroid cancer, arising from the thyroid's hormone-producing follicular cells. It's treated with surgery and radioiodine, with targeted therapy such as sorafenib for cases that stop responding.
Key facts
- Differentiated thyroid carcinoma (DTC) covers the two most common forms of thyroid cancer, papillary and follicular, both arising from the thyroid's hormone-producing follicular cells.
- DTC accounts for over 90% of all thyroid cancers and generally carries a favourable long-term outlook, particularly when caught before it spreads beyond the neck.
- Most DTC is managed with surgery to remove part or all of the thyroid, often followed by radioiodine therapy to destroy any remaining thyroid tissue.
- When the cancer stops responding to radioiodine (radioiodine-refractory DTC), targeted oncology treatment such as sorafenib becomes the next step.
Symptoms and diagnosis
DTC is most often found as a painless lump or nodule in the neck, sometimes noticed by the person themselves or picked up during a routine examination. Thyroid hormone levels usually stay normal, since the tumour rarely disrupts overall gland function, so blood tests alone won't find it. Diagnosis relies on neck ultrasound followed by a needle biopsy of any suspicious nodule, with the biopsy result guiding whether surgery is needed.
When standard treatment isn't enough
Most DTC is managed with surgery to remove part or all of the thyroid, often followed by radioiodine therapy to destroy any remaining thyroid tissue or spread. For a minority of patients, the cancer stops responding to radioiodine, called radioiodine-refractory DTC, and the disease continues to progress. In that setting, targeted oncology treatment becomes the next step.
The kinase inhibitor sorafenib is approved for radioiodine-refractory, locally advanced or metastatic DTC. It works by blocking signals that drive tumour growth and blood vessel formation, slowing progression in cancers that have lost their sensitivity to radioiodine. It sits within the wider oncology range of cancer treatments.
When to see a doctor
Any change in symptoms, a rapidly growing neck lump, hoarseness that persists, or difficulty swallowing, warrants prompt assessment by a specialist.
This page is educational and does not replace advice from a doctor or pharmacist who knows your health history.